Epigenetics in alzheimer's disease: A focus on dna modifications

Current Pharmaceutical Design

Volumn 17, Issue 31, 2011, Pages 3398-3412

  Coppieters, Natacha ^a   Dragunow, Mike ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

5 hydroxymethylcytosine; 5 methylcytosine; Alzheimer's disease; Dna methylation; Environment; Epigenetics

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ARSENIC; ASCORBIC ACID; CASPASE 3; CYANOCOBALAMIN; CYTOSINE; DNA METHYLTRANSFERASE 1; FOLIC ACID; HOMOCYSTEINE; LEAD; MESSENGER RNA; METHYLTRANSFERASE; PYRIDOXINE; TAU PROTEIN; TOBACCO SMOKE; TRACE ELEMENT;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CARBON METABOLISM; CLINICAL TRIAL (TOPIC); DEMENTIA; DIET; DISEASE ASSOCIATION; DNA DAMAGE; DNA METHYLATION; DNA MODIFICATION; ENVIRONMENTAL FACTOR; EPIGENETICS; FOLATE METABOLISM; FOLIC ACID DEFICIENCY; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STRESS;

ALZHEIMER DISEASE; AMYLOID; BRAIN; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS;

EID: 80055088590     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798072544     Document Type: Article

References (210)

1. Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol Aging 1998; 19: 173-89.
2. Finder VH. Alzheimer's disease: a general introduction and path-omechanism. J Alzheimers Dis 2010; 22 Suppl 3: 5-19.
3. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res 2010; 33: 1539-56.
4. Lynch AM, Murphy KJ, Deighan BF, et al. The Impact of Glial Activation in the Aging Brain. Aging and Disease 2010; 1: 262-78.
5. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009; 118: 5-36.
6. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 2010; 23: 213-27.
7. Bi X. Alzheimer disease: update on basic mechanisms. J Am Os-teopath Assoc 2010; 110: S3-9.
8. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-5.
9. Armstrong RA. The pathogenesis of Alzheimer's disease: a re-evaluation of the amyloid cascade hypothesis. Int J Alzheimers Dis 2011; 2011: 630865.
10. Herrup K. Reimagining Alzheimer's disease--an age-based hy-pothesis. J Neurosci 2010; 30: 16755-62.
11. Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, Droller D. Early environmental origins of neurodegenerative dis-ease in later life. Environ Health Perspect 2005; 113: 1230-3.
12. Perera F, Herbstman J. Prenatal environmental exposures, epigenet-ics, and disease. Reprod Toxicol 2011; 31: 363-73.
13. Miller DB, O'Callaghan JP. Do early-life insults contribute to the late-life development of Parkinson and Alzheimer diseases? Me-tabolism 2008; 57 Suppl 2: S44-9.
14. Murgatroyd C, Patchev AV, Wu Y, et al. Dynamic DNA methyla-tion programs persistent adverse effects of early-life stress. Nat Neurosci 2009; 12: 1559-66.
15. Finch CE. Developmental origins of aging in brain and blood ves-sels: an overview. Neurobiol Aging 2005; 26: 281-91.
16. Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B. Early-life events may trigger biochemical pathways for Alzheimer's disease: the LEARn model. Biogerontology 2008; 9: 375-9.
17. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64: 93-6.
18. Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabe-tes accelerate Alzheimer disease pathology? Nat Rev Neurol 2011; 6: 551-9.
19. Hassing LB, Dahl AK, Thorvaldsson V, et al. Overweight in mid-life and risk of dementia: a 40-year follow-up study. Int J Obes (Lond) 2009; 33: 893-8.
20. Aguilera O, Fernandez AF, Munoz A, Fraga MF. Epigenetics and environment: a complex relationship. J Appl Physiol 2010; 109: 243-51.
21. Graff J, Mansuy IM. Epigenetic dysregulation in cognitive disor-ders. Eur J Neurosci 2009; 30: 1-8.
22. Ling C, Groop L. Epigenetics: a molecular link between environ-mental factors and type 2 diabetes. Diabetes 2009; 58: 2718-25.
23. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057-68.
24. Narayan P, Dragunow M. Pharmacology of epigenetics in brain disorders. Br J Pharmacol 2009; 159: 285-303.
25. Ma DK, Marchetto MC, Guo JU, Ming GL, Gage FH, Song H. Epigenetic choreographers of neurogenesis in the adult mammalian brain. Nat Neurosci 2010; 13: 1338-44.
26. Riccio A. Dynamic epigenetic regulation in neurons: enzymes, stimuli and signaling pathways. Nat Neurosci 2010; 13: 1330-7.
27. Chouliaras L, Rutten BP, Kenis G, et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol 2010; 90: 498-510.
28. Dahl C, Gronbaek K, Guldberg P. Advances in DNA methylation: 5-hydroxymethylcytosine revisited. Clin Chim Acta 2011; 412: 831-6.
29. Song CX, Szulwach KE, Fu Y, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 2010; 29: 68-72.
30. Marques SC, Oliveira CR, Pereira CM, Outeiro TF. Epigenetics in neurodegeneration: A new layer of complexity. Prog Neuropsycho-pharmacol Biol Psychiatry 2010; 35 348-55.
31. Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiewicz D, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and in-volves differentiated neurons. PLoS One 2007; 2: e895.
32. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009; 462: 315-22.
33. Straussman R, Nejman D, Roberts D, et al. Developmental pro-gramming of CpG island methylation profiles in the human ge-nome. Nat Struct Mol Biol 2009; 16: 564-71.
34. Fulka H, St John JC, Fulka J, Hozak P. Chromatin in early mam-malian embryos: achieving the pluripotent state. Differentiation 2008; 76: 3-14.
35. Elango N, Yi SV. Functional Relevance of CpG island Length for Regulation of Gene Expression. Genetics 2011; 187: 1077-83.
36. Hermann A, Gowher H, Jeltsch A. Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 2004; 61: 2571-87.
37. Hermann A, Goyal R, Jeltsch A. The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high prefer-ence for hemimethylated target sites. J Biol Chem 2004; 279: 48350-9.
38. Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009; 10: 805-11.
39. Cedar H, Bergman Y. Linking DNA methylation and histone modi-fication: patterns and paradigms. Nat Rev Genet 2009; 10: 295-304.
40. Wienholz BL, Kareta MS, Moarefi AH, Gordon CA, Ginno PA, Chedin F. DNMT3L modulates significant and distinct flanking se-quence preference for DNA methylation by DNMT3A and DNMT3B in vivo. PLoS Genet 2010; 6: e1001106.
41. Xu F, Mao C, Ding Y, et al. Molecular and enzymatic profiles of mammalian DNA methyltransferases: structures and targets for drugs. Curr Med Chem 2010; 17: 4052-71.
42. Holz-Schietinger C, Reich NO. The inherent processivity of the human de novo methyltransferase 3A (DNMT3A) is enhanced by DNMT3L. J Biol Chem 2010; 285: 29091-100.
43. Schaefer M, Lyko F. Solving the Dnmt2 enigma. Chromosoma 2010; 119: 35-40.
44. Thiagarajan D, Dev RR, Khosla S. The DNA methyltranferase Dnmt2 participates in RNA processing during cellular stress. Epi-genetics 2011; 6: 103-13.
45. Schaefer M, Pollex T, Hanna K, et al. RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage. Genes Dev 2010; 24: 1590-5.
46. Cheng X. DNA modification by methyltransferases. Curr Opin Struct Biol 1995; 5: 4-10.
47. Schar P, Fritsch O. DNA repair and the control of DNA methyla-tion. Prog Drug Res 2011; 67: 51-68.
48. Chen ZX, Riggs AD. DNA methylation and demethylation in mammals. J Biol Chem 2011; 286: 18347-53.
49. Cardoso MC, Leonhardt H. DNA methyltransferase is actively retained in the cytoplasm during early development. J Cell Biol 1999; 147: 25-32.
50. Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 2010; 11: 607-20.
51. Kaneda M, Okano M, Hata K, et al. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprint-ing. Nature 2004; 429: 900-3.
52. Reik W, Walter J. Genomic imprinting: parental influence on the genome. Nat Rev Genet 2001; 2: 21-32.
53. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002; 3: 662-73.
54. Metivier R, Gallais R, Tiffoche C, et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008; 452: 45-50.
55. Penn NW, Suwalski R, O'Riley C, Bojanowski K, Yura R. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem J 1972; 126: 781-90.
56. Szwagierczak A, Bultmann S, Schmidt CS, Spada F, Leonhardt H. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res 2010; 38: e181.
57. Globisch D, Munzel M, Muller M, et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation inter-mediates. PLoS One 2010; 5: e15367.
58. Shock LS, Thakkar PV, Peterson EJ, Moran RG, Taylor SM. DNA methyltransferase 1, cytosine methylation, and cytosine hy-droxymethylation in mammalian mitochondria. Proc Natl Acad Sci USA 2011; 108: 3630-5.
59. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-5.
60. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxy-methylcytosine is present in Purkinje neurons and the brain. Sci-ence 2009; 324: 929-30.
61. Munzel M, Globisch D, Bruckl T, et al. Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl 2010; 49: 5375-7.
62. Ficz G, Branco MR, Seisenberger S, et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentia-tion. Nature 2011; 473: 398-402.
63. Williams K, Christensen J, Pedersen MT, et al. TET1 and hy-droxymethylcytosine in transcription and DNA methylation fidel-ity. Nature 2011; 473: 343-8.
64. Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5- hydroxymethylcytosine in embryonic stem cells. Nature 2011; 473: 394-7.
65. Wu H, D'Alessio AC, Ito S. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells Genes Dev 2011; 25: 679-84.
66. Wu H, D'Alessio AC, Ito S, et al. Dual functions of Tet1 in tran-scriptional regulation in mouse embryonic stem cells. Nature 2011; 473: 389-93.
67. Zhang H, Zhang X, Clark E, Mulcahey M, Huang S, Shi YG. TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res 2010; 20: 1390-3.
68. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-33.
69. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the bind-ing of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res 2004; 32: 4100-8.
70. Jin SG, Wu X, Li AX, Pfeifer GP. Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nucleic Acids Res 2011.
71. Iqbal K, Jin SG, Pfeifer GP, Szabo PE. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc Natl Acad Sci USA 2011; 108: 3642-7.
72. Jin SG, Kadam S, Pfeifer GP. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res 2010; 38: e125.
73. Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult Brain. Cell 2011; 145: 423-34.
74. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltrans-ferase DNMT1. Cancer Res 2007; 67: 946-50.
75. Wu J, Basha MR, Brock B, et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environ-mental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 2008; 28: 3-9.
76. Fulka H, Mrazek M, Tepla O, Fulka J, Jr. DNA methylation pattern in human zygotes and developing embryos. Reproduction 2004; 128: 703-8.
77. Wossidlo M, Nakamura T, Lepikhov K, et al. 5-Hydroxy-methylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat Commun 2011; 2: 241.
78. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247-57.
79. Yakovlev A, Khafizova M, Abdullaev Z, Loukinov D, Kondratyev A. Epigenetic regulation of caspase-3 gene expression in rat brain development. Gene 2010; 450: 103-8.
80. Curtis MA, Kam M, Faull RL. Neurogenesis in humans. Eur J Neurosci 2011; 33: 1170-4.
81. Curtis MA, Kam M, Nannmark U, et al. Human neuroblasts mi-grate to the olfactory bulb via a lateral ventricular extension. Sci-ence 2007; 315: 1243-9.
82. Sun J, Ming GL, Song H. Epigenetic regulation of neurogenesis in the adult mammalian brain. Eur J Neurosci 2011; 33: 1087-93.
83. Ladd-Acosta C, Pevsner J, Sabunciyan S, et al. DNA methylation signatures within the human brain. Am J Hum Genet 2007; 81: 1304-15.
84. Hernandez DG, Nalls MA, Gibbs JR, et al. Distinct DNA methyla-tion changes highly correlated with chronological age in the human brain. Hum Mol Genet 2011; 20: 1164-72.
85. Gibbs JR, van der Brug MP, Hernandez DG, et al. Abundant quan-titative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet 2010; 6: e1000952.
86. Pogribny IP, Vanyushin BF. Age-related Genomic Hypomethyla-tion. In: Tollefsbol TO, ed. Epigenetics of Aging: Springer 2009; 11-27.
87. Agrawal A, Tay J, Yang GE, Agrawal S, Gupta S. Age-associated epigenetic modifications in human DNA increase its immunogenic-ity. Aging (Albany NY) 2010; 2: 93-100.
88. Jintaridth P, Mutirangura A. Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. Physiol Ge-nomics 2010; 41: 194-200.
89. Zilberman D, Henikoff S. Genome-wide analysis of DNA methyla-tion patterns. Development 2007; 134: 3959-65.
90. Huang Y, Pastor WA, Shen Y, Tahiliani M, Liu DR, Rao A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One 2010; 5: e8888.
91. Robertson AB, Dahl JA, Vagbo CB, Tripathi P, Krokan HE, Klungland A. A novel method for the efficient and selective identi-fication of 5-hydroxymethylcytosine in genomic DNA. Nucleic Ac-ids Res 2011; 39: e55.
92. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic changes in Alzheimer's disease: Decrements in DNA methylation. Neurobiol Aging 2010; 31: 2025-37.
93. Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD. Epige-netic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One 2009; 4: e6617.
94. Adkins RM, Krushkal J, Tylavsky FA, Thomas F. Racial differ-ences in gene-specific DNA methylation levels are present at birth. Birth Defects Res A Clin Mol Teratol 2011.
95. Takasugi M. Progressive age-dependent DNA methylation changes start before adulthood in mouse tissues. Mech Ageing Dev 2011; 132: 65-71.
96. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
97. LaFerla FM. Pathways linking Abeta and tau pathologies. Biochem Soc Trans 2010; 38: 993-5.
98. Ittner LM, Gotz J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12: 65-72.
99. Chen KL, Yuan RY, Hu CJ, Hsu CY. Amyloid-beta peptide altera-tion of tau exon-10 splicing via the GSK3beta-SC35 pathway. Neu-robiol Dis 2010; 40: 378-85.
100. Li QX, Fuller SJ, Beyreuther K, Masters CL. The amyloid precur-sor protein of Alzheimer disease in human brain and blood. J Leu-koc Biol 1999; 66: 567-74.
101. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998; 8: 447-53.
102. Rogaev EI, Lukiw WJ, Lavrushina O, Rogaeva EA, St George-Hyslop PH. The upstream promoter of the beta-amyloid precursor protein gene (APP) shows differential patterns of methylation in human brain. Genomics 1994; 22: 340-7.
103. Niederwolfsgruber E, Schmitt TL, Blasko I, et al. The production of the Alzheimer amyloid precursor protein (APP) in extraneuronal tissue does not increase in old age. J Gerontol A Biol Sci Med Sci1998; 53: B186-90.
104. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 499-509.
105. Steiner H, Capell A, Leimer U, Haass C. Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999; 249: 266-70.
106. Chou WG, Zain SB, Rehman S, et al. Alzheimer cortical neurons containing abundant amyloid mRNA. Relationship to amyloid deposition and senile plaques. J Psychiatr Res 1990; 24: 37-50.
107. Goedert M. Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer's disease. EMBO J 1987; 6: 3627-32.
108. Preece P, Virley DJ, Costandi M, et al. Amyloid precursor protein mRNA levels in Alzheimer's disease brain. Brain Res Mol Brain Res 2004; 122: 1-9.
109. Causevic M, Farooq U, Lovestone S, Killick R. beta-Amyloid precursor protein and tau protein levels are differently regulated in human cerebellum compared to brain regions vulnerable to Alz- heimer's type neurodegeneration. Neurosci Lett 2010; 485: 162-6.
110. Ledoux S, Bergeron C, Nalbantoglu J, Gauthier S, Cashman NR. Polymerase chain reaction quantification of lymphoid amyloid pre-cursor protein mRNAs in Alzheimer's disease and Down's syn-drome. Neurosci Lett 1995; 193: 137-9.
111. Jiang S, Zhang M, Ren D, et al. Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2003; 118B: 99-102.
112. Ebstein RP, Nemanov L, Lubarski G, Dano M, Trevis T, Korczyn AD. Changes in expression of lymphocyte amyloid precursor pro-tein mRNA isoforms in normal aging and Alzheimer's disease. Brain Res Mol Brain Res 1996; 35: 260-8.
113. Padovani A, Borroni B, Colciaghi F, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol 2002; 59: 71-5.
114. Di Luca M, Pastorino L, Cattabeni F, et al. Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch Neurol 1996; 53: 1162-6.
115. Tanaka S, Nakamura S, Kimura J, Ueda K. Age-related change in the proportion of amyloid precursor protein mRNAs in the gray matter of cerebral cortex. Neurosci Lett 1993; 163: 19-21.
116. Maunakea AK, Nagarajan RP, Bilenky M, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010; 466: 253-7.
117. Yu Y, Zhang H, Byerly MS, et al. Alternative splicing variants and DNA methylation status of BDNF in inbred chicken lines. Brain Res 2009; 1269: 1-10.
118. Li YY, Chen T, Wan Y, Xu SQ. Lead exposure in pheochromocy-toma cells induces persistent changes in amyloid precursor protein gene methylation patterns. Environ Toxicol 2010.
119. Ledoux S, Nalbantoglu J, Cashman NR. Amyloid precursor protein gene expression in neural cell lines: influence of DNA cytosine methylation. Brain Res Mol Brain Res 1994; 24: 140-4.
120. West RL, Lee JM, Maroun LE. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease pa-tient. J Mol Neurosci 1995; 6: 141-6.
121. Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol 2009; 68: 880-91.
122. Brohede J, Rinde M, Winblad B, Graff C. A DNA methylation study of the amyloid precursor protein gene in several brain regions from patients with familial Alzheimer disease. J Neurogenet 2010; 24: 179-81.
123. Scarpa S, Fuso A, D'Anselmi F, Cavallaro RA. Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer dis-ease? FEBS Lett 2003; 541: 145-8.
124. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008; 18: 240-52.
125. Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively stud-ied elderly and Alzheimer's brain. J Neurochem 2010; 115: 47-57.
126. Miners JS, van Helmond Z, Kehoe PG, Love S. Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-convertingenzyme. Brain Pathol 2010; 20: 794-802.
127. Chen KL, Wang SS, Yang YY, Yuan RY, Chen RM, Hu CJ. The epigenetic effects of amyloid-beta(1-40) on global DNA and ne-prilysin genes in murine cerebral endothelial cells. Biochem Bio-phys Res Commun 2009; 378: 57-61.
128. Hong Y, Beckett C, Belyaev ND, Turner AJ. The impact of amy-loid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells. Int J Cancer 2011.
129. Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 2009; 10: 94-100.
130. Deshpande A, Win KM, Busciglio J. Tau isoform expression and regulation in human cortical neurons. FASEB J 2008; 22: 2357-67.
131. Nicolia V, Fuso A, Cavallaro RA, Di Luzio A, Scarpa S. B vitamin deficiency promotes tau phosphorylation through regulation of GSK3beta and PP2A. J Alzheimers Dis 2010; 19: 895-907.
132. Qian W, Shi J, Yin X, et al. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 2010; 19: 1221-9.
133. Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neu-ropathol Appl Neurobiol 2007; 33: 43-55.
134. Hye A, Kerr F, Archer N, et al. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett 2005; 373: 1-4.
135. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: de-crease in Alzheimer disease brain. J Neurochem 1995; 65: 732-8.
136. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 2001; 168: 402-12.
137. Sontag E, Hladik C, Montgomery L, et al. Downregulation of pro-tein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol 2004; 63: 1080-91.
138. Sontag E, Luangpirom A, Hladik C, et al. Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associ-ated with Alzheimer disease pathology. J Neuropathol Exp Neurol 2004; 63: 287-301.
139. Sontag E, Nunbhakdi-Craig V, Sontag JM, et al. Protein phospha-tase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci 2007; 27: 2751-9.
140. Sunahori K, Juang YT, Tsokos GC. Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and ac-tivity. J Immunol 2009; 182: 1500-8.
141. Sunahori K, Juang YT, Kyttaris VC, Tsokos GC. Promoter Hy-pomethylation Results in Increased Expression of Protein Phospha-tase 2A in T Cells from Patients with Systemic Lupus Erythemato-sus. J Immunol 2011; 186: 4508-17.
142. Coppede F. One-carbon metabolism and Alzheimer's disease: focuson epigenetics. Curr Genomics 2010; 11: 246-60.
143. Tchantchou F. Homocysteine metabolism and various conse-quences of folate deficiency. J Alzheimers Dis 2006; 9: 421-7.
144. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19:217-46.
145. Herrmann W, Obeid R. Homocysteine: a biomarker in neurodegen-erative diseases. Clin Chem Lab Med 2011; 49: 435-41.
146. Fuso A, Nicolia V, Cavallaro RA, Scarpa S. DNA methylase and demethylase activities are modulated by one-carbon metabolism in Alzheimer's disease models. J Nutr Biochem 2011; 22: 242-51.
147. Patra SK, Patra A, Rizzi F, Ghosh TC, Bettuzzi S. Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. Cancer Metastasis Rev 2008; 27: 315-34.
148. Linnebank M, Popp J, Smulders Y, et al. S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease. Neurodegener Dis 2010; 7: 373-8.
149. Cito A, Porcelli B, Coppola MG, Mangiavacchi P, Cortelazzo A, Terzuoli L. Analysis of serum levels of homocysteine and oxidative stress markers in patients with Alzheimer disease. Biomed Pharma-cother 2010.
150. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-83.
151. Hooshmand B, Solomon A, Kareholt I, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudi-nal study. Neurology 2010; 75: 1408-14.
152. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005; 28: 195-204.
153. Fuso A, Nicolia V, Cavallaro RA, et al. B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci2008; 37: 731-46.
154. Fuso A, Nicolia V, Pasqualato A, Fiorenza MT, Cavallaro RA, Scarpa S. Changes in Presenilin 1 gene methylation pattern in diet- induced B vitamin deficiency. Neurobiol Aging 2011; 32: 187-99.
155. Zhuo JM, Pratico D. Acceleration of brain amyloidosis in an Alz-heimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol 2010; 45: 195-201.
156. Pirchl M, Ullrich C, Humpel C. Differential effects of short- and long-term hyperhomocysteinaemia on cholinergic neurons, spatial memory and microbleedings in vivo in rats. Eur J Neurosci 2010; 32: 1516-27.
157. Singh R, Kanwar SS, Sood PK, Nehru B. Beneficial effects of folic acid on enhancement of memory and antioxidant status in aged rat brain. Cell Mol Neurobiol 2011; 31: 83-91.
158. Liu CC, Ho WY, Leu KL, Tsai HM, Yang TH. Effects of S-adenosylhomocysteine and homocysteine on DNA damage and cell cytotoxicity in murine hepatic and microglia cell lines. J Biochem Mol Toxicol 2009; 23: 349-56.
159. Politis A, Olgiati P, Malitas P, et al. Vitamin B12 levels in Alz-heimer's disease: association with clinical features and cytokine production. J Alzheimers Dis 2010; 19: 481-8.
160. Lin HC, Hsieh HM, Chen YH, Hu ML. S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by in-creased expressions of beta-amyloid precursor protein and preseni-lin 1 and by hypomethylation of these gene promoters. Neurotoxi-cology 2009; 30: 622-7.
161. Day JJ, Sweatt JD. Cognitive neuroepigenetics: A role for epige-netic mechanisms in learning and memory Neurobiol Learn Mem 2011.
162. Liu L, van Groen T, Kadish I, Tollefsbol TO. DNA methylation impacts on learning and memory in aging. Neurobiol Aging 2009; 30: 549-60.
163. Selhub J, Troen A, Rosenberg IH. B vitamins and the aging brain. Nutr Rev 2010; 68 Suppl 2: 112-118
164. Ford AH, Flicker L, Alfonso H, et al. Vitamins B(12), B(6), and folic acid for cognition in older men. Neurology 2010; 75: 1540-7.
165. Anderson CA, Jee SH, Charleston J, Narrett M, Appel LJ. Effects of folic acid supplementation on serum folate and plasma homocys-teine concentrations in older adults: a dose-response trial. Am J Epidemiol 2010; 172: 932-41.
166. Kwok T, Lee J, Law CB, et al. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr 2011; 30: 297-302.
167. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008: CD004514.
168. Nelson C, Wengreen HJ, Munger RG, Corcoran CD. Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: the cache county memory, health and aging study. J Nutr Health Aging 2009; 13: 899-905.
169. Sun Y, Lu CJ, Chien KL, Chen ST, Chen RC. Efficacy of multivi-tamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alz-heimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin Ther 2007; 29: 2204-14.
170. Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alz-heimer Dis Assoc Disord 2000; 14 Suppl 1: S47-53.
171. Scalabrino G, Carpo M, Bamonti F, et al. High tumor necrosis factor-alpha [corrected] levels in cerebrospinal fluid of cobalamin-deficient patients. Ann Neurol 2004; 56: 886-90.
172. Bayarsaihan D. Epigenetic mechanisms in inflammation. J Dent Res 2011; 90: 9-17.
173. Jin Y, Amaral A, McCann A, Brennan L. Homocysteine levels impact directly on epigenetic reprogramming in astrocytes. Neuro-chem Int 2011.
174. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005; 102: 10604-9.
175. Kaminsky ZA, Tang T, Wang SC, et al. DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet 2009; 41: 240-5.
176. Wong CC, Caspi A, Williams B, et al. A longitudinal study of epigenetic variation in twins. Epigenetics 2010; 5: 516-26.
177. Ren X, McHale CM, Skibola CF, Smith AH, Smith MT, Zhang L. An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ Health Perspect 2011; 119: 11-9.
178. Dani SU. Arsenic for the fool: an exponential connection. Sci Total Environ 2010; 408: 1842-6.
179. Cataldo JK, Prochaska JJ, Glantz SA. Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis 2010; 19: 465-80.
180. Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. Am J Respir Crit Care Med 2009; 180: 462-7.
181. Satta R, Maloku E, Zhubi A, et al. Nicotine decreases DNA meth-yltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons. Proc Natl Acad Sci USA 2008; 105: 16356-61.
182. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. Arch Neurol 2010; 67: 699-706.
183. Li C, Xu M, Wang S, Yang X, Zhou S, Zhang J, et al. Lead expo-sure suppressed ALAD transcription by increasing methylation level of the promoter CpG islands. Toxicol Lett 2011; 203: 48-53.
184. Cory-Slechta DA, Virgolini MB, Rossi-George A, Thiruchelvam M, Lisek R, Weston D. Lifetime consequences of combined mater-nal lead and stress. Basic Clin Pharmacol Toxicol 2008; 102: 218-227.
185. Surkan PJ, Zhang A, Trachtenberg F, Daniel DB, McKinlay S, Bellinger DC. Neuropsychological function in children with blood lead levels <10 microg/dL. Neurotoxicology 2007; 28: 1170-7.
186. Jomova K, Jenisova Z, Feszterova M, et al. Arsenic: toxicity, oxi-dative stress and human disease. J Appl Toxicol 2011; 31: 95-107.
187. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Medi-terranean diet and risk for Alzheimer's disease. Ann Neurol 2006; 59: 912-21.
188. Allen LH. How common is vitamin B-12 deficiency? Am J Clin Nutr 2009; 89: 693S-6S.
189. Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010; 345: 91-104.
190. Chung TL, Brena RM, Kolle G, et al. Vitamin C promotes wide-spread yet specific DNA demethylation of the epigenome in human embryonic stem cells. Stem Cells 2010; 28: 1848-55.
191. Markesbery WR, Lovell MA. DNA oxidation in Alzheimer's dis-ease. Antioxid Redox Signal 2006; 8: 2039-45.
192. Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adh Migr 2009; 3: 88-93.
193. Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 2009; 46: 1241-9.
194. Flora SJ. Arsenic-induced oxidative stress and its reversibility. Free Radic Biol Med 2011.
195. Pogribny IP, Shpyleva SI, Muskhelishvili L, Bagnyukova TV, James SJ, Beland FA. Role of DNA damage and alterations in cy-tosine DNA methylation in rat liver carcinogenesis induced by a methyl-deficient diet. Mutat Res 2009; 669: 56-62.
196. Unnikrishnan A, Prychitko TM, Patel HV, et al. Folate deficiency regulates expression of DNA polymerase beta in response to oxida-tive stress. Free Radic Biol Med 2011; 50: 270-80.
197. Rammal H, Bouayed J, Younos C, Soulimani R. Evidence that oxidative stress is linked to anxiety-related behaviour in mice. Brain Behav Immun 2008; 22: 1156-9.
198. Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 2010; 69: 155-67.
199. Vural H, Demirin H, Kara Y, Eren I, Delibas N. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in pa-tients with Alzheimer's disease. J Trace Elem Med Biol 2010; 24: 169-73.
200. Wan L, Nie G, Zhang J, et al. beta-Amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radic Biol Med 2011; 50: 122-9.
201. Hyun DH, Mughal MR, Yang H, et al. The plasma membrane redox system is impaired by amyloid beta-peptide and in the hippo-campus and cerebral cortex of 3xTgAD mice. Exp Neurol 2010; 225: 423-9.
202. Nunomura A, Tamaoki T, Tanaka K, et al. Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alz-heimer disease. Neurobiol Dis 2010; 37: 731-7.
203. Patra RC, Rautray AK, Swarup D. Oxidative stress in lead and cadmium toxicity and its amelioration. Vet Med Int 2011; 2011: 457327.
204. Ghosh R, Mitchell DL. Effect of oxidative DNA damage in pro-moter elements on transcription factor binding. Nucleic Acids Res 1999; 27: 3213-8.
205. Turk PW, Laayoun A, Smith SS, Weitzman SA. DNA adduct 8-hydroxyl-2'-deoxyguanosine (8-hydroxyguanine) affects function of human DNA methyltransferase. Carcinogenesis 1995; 16: 1253-5.
206. Weitzman SA, Turk PW, Milkowski DH, Kozlowski K. Free radi-cal adducts induce alterations in DNA cytosine methylation. Proc Natl Acad Sci USA 1994; 91: 1261-4.
207. Guz J, Foksinski M, Siomek A, et al. The relationship between 8-oxo-7,8-dihydro-2'-deoxyguanosine level and extent of cytosine methylation in leukocytes DNA of healthy subjects and in patients with colon adenomas and carcinomas. Mutat Res 2008; 640: 170-3.
208. Zelko IN, Mueller MR, Folz RJ. CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression. Free Radic Biol Med 2010; 48: 895-904.
209. Chen TF, Huang RF, Lin SE, Lu JF, Tang MC, Chiu MJ. Folic Acid potentiates the effect of memantine on spatial learning and neuronal protection in an Alzheimer's disease transgenic model. J Alzheimers Dis 2010; 20: 607-15.
210. Rainer M, Wuschitz A, Jagsch C, Erb C, Chirikdjian JJ, Mucke HA. Memantine in moderate to severe Alzheimer's disease: an ob-servational post-marketing study. J Neural Transm 2011.